ESPE Abstracts (2014) 82 P-D-3-1-668

Lumbar Spine Areal Bone Mineral Density and 25-Hydroxyvitamin D Serum Concentrations at 2-Year Follow-up in Patients with Osteogenesis Imperfecta

Claudia Piona, Giovanni Moser, Diego Ramaroli, Malesani Francesca, Grazia Morandi, Rossella Gaudino & Franco Antoniazzi


Department of Life and Reproduction Sciences Pediatric Clinic, University of Verona, Verona, Italy


Background: Cyclic treatment with bisphosphonates (BP) is now considered a ‘standard care’ for children with osteogenesis imperfecta (OI). Vitamin D is a necessary nutrient for bone health for all children but especially for those with OI. In the literature few studies have considered the relationship between bone mineral density, vitamin D and pubertal stage in children treated with BP for OI.

Objective and hypotheses: The purpose of this study is to evaluate the vitamin D status and to asses the relationship between 25-hydroxyvitamin D (25OH-D) level, pubertal stage and the variation in lumbar spine areal bone mineral density (LS-aBMD) measurements during a 2-year follow-up in children with OI.

Method: This retrospective study comprised 28 patients affected by OI treated with neridronate for at least 4 years. Charts of these 25 patients were reviewed for mean 25OH-D level and mean variation in LS-aBMD (%ΔBMD) in 2-years follow-up. The patient cohort was divided into three groups according to pubertal stage: prepubertal group (SP1), pubertal group (SP2) and postpubertal group (SP3). Each group was divided into two subgroups numerically similar according to 25OH-D serum concentrations (A:>26 ng/ml; B:<26 ng/ml).

Results: Almost 60% of our patients have insufficient (<30 ng/ml) or deficient (<20 ng/ml) level of 25OH-D. The mean serum 25OH-D concentrations was 28.9 ng/ml (SP1 35.58±15.48 ng/ml; SP2 25.24±5.62 ng/ml; SP3 25.9±8.81 ng/ml). In prepubertal SP1 and postpubertal SP3 subgroups BMD improved, but not significantly, during the 2-years follow-up (%ΔBMD SP1 A:18%, B:14%, P:0.271; %ΔBMD SP3 A:5%, B:6.93%, P:0.322). In pubertal subgroup SP2%ΔBMD increased more in patients of subgroup A respect patients of subgroup B, with a significantly difference between the two subgroups (%ΔBMD SP2 A: 27.72%, B:11.84%, P:0.029).

Conclusion: We find a positive association between high vitamin D status and LS-aBMD in pubertal patients with OI.Stable vitamine D level above 30 ng/ml during pubertal development may keep low PTH level decreasing bone resorption and potently stimulate the increase of bone mass during treatment with BP in adolescents with OI.

Article tools

My recent searches

No recent searches.